Effect of doxepin and nortriptyline on irritable bowel syndrome

comparative survey of the effect of doxepin and nortriptyline on diarrhea-predominant irritable bowel syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138903114017N3

Enrollment

Registered

2010-06-12

Start date

2010-06-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diarrhea predominant irritable bowel syndrome.

Interventions

Intervention 1: Doxepin,tablet 10 mg oral,once daily for 2 months. Intervention 2: Nortriptyline,tablet 10 mg oral,once daily for 2 months.

Treatment - Drugs

Doxepin,tablet 10 mg oral,once daily for 2 months

Nortriptyline,tablet 10 mg oral,once daily for 2 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: presence of diarrhea predominant irritable bowel syndrome according to ROME criteria Exclusion criteria: Gastrointestinal bleeding, More than 5% weight loss in the last 6 months, presence of any finding in favor of organic disorders in the lab tests or organic disorder in colonoscopy of high risk patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Abdominal pain. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of pain.;Mucus in the stool. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of mucus in the stool.;Bloating. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of bloating.;Incomplete evacuation. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of Incomplete evacuation.	—

Measure

Time frame

Abdominal pain. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of pain.;Mucus in the stool. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of mucus in the stool.;Bloating. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of bloating.;Incomplete evacuation. Timepoint: prior to intervention- 1 month after intervention- 2 month after intervention. Method of measurement: visual scale of Incomplete evacuation.

—

Secondary

Measure	Time frame
Somnolence. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: visual scale of somnolence.;Constipation. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: visual scale of constipation.;Urinary retention. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: visual scale of urinary retention.;Tachycardia. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: pulse examination.	—

Measure

Time frame

Somnolence. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: visual scale of somnolence.;Constipation. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: visual scale of constipation.;Urinary retention. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: visual scale of urinary retention.;Tachycardia. Timepoint: prior to intervention-1 month after intervention-2 months after intervention. Method of measurement: pulse examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHosseinali habibinejad

Islamic Azad University of Qom

ali.medicine@yahoo.com+98 25 1720 8392

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026